Split PTAB Invalidates Some Leukemia Drug Patent Claims
A split panel of Patent Trial and Appeal Board judges has decided that some of the claims in a patent covering an AbbVie Inc. leukemia drug were not written specifically enough...To view the full article, register now.
Already a subscriber? Click here to view full article